618 related articles for article (PubMed ID: 8536553)
1. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.
Goa KL; Barradell LB
Drugs; 1995 Oct; 50(4):658-90. PubMed ID: 8536553
[TBL] [Abstract][Full Text] [Related]
2. Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses.
Grant SM; Clissold SP
Drugs; 1990 Jun; 39(6):877-916. PubMed ID: 2196167
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.
Debruyne D
Clin Pharmacokinet; 1997 Jul; 33(1):52-77. PubMed ID: 9250423
[TBL] [Abstract][Full Text] [Related]
4. Antifungal prophylaxis in immunocompromised hosts.
Reents S; Goodwin SD; Singh V
Ann Pharmacother; 1993 Jan; 27(1):53-60. PubMed ID: 8431623
[TBL] [Abstract][Full Text] [Related]
5. Current drug therapy of systemic mycoses: a review.
Yonga G
East Afr Med J; 1995 Jun; 72(6):394-8. PubMed ID: 7498014
[TBL] [Abstract][Full Text] [Related]
6. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
7. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America.
Saag MS; Graybill RJ; Larsen RA; Pappas PG; Perfect JR; Powderly WG; Sobel JD; Dismukes WE
Clin Infect Dis; 2000 Apr; 30(4):710-8. PubMed ID: 10770733
[TBL] [Abstract][Full Text] [Related]
8. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group.
Wolff SN; Fay J; Stevens D; Herzig RH; Pohlman B; Bolwell B; Lynch J; Ericson S; Freytes CO; LeMaistre F; Collins R; Pineiro L; Greer J; Stein R; Goodman SA; Dummer S
Bone Marrow Transplant; 2000 Apr; 25(8):853-9. PubMed ID: 10808206
[TBL] [Abstract][Full Text] [Related]
9. Therapy for opportunistic fungal infections: past, present and future.
Stevens DA
Indian J Cancer; 1995 Mar; 32(1):1-9. PubMed ID: 7558104
[TBL] [Abstract][Full Text] [Related]
10. Use of antifungal therapy in hospitalized patients. I. Results prior to the marketing of fluconazole.
Grasela TH; Goodwin SD; Pasko MT; Walawander CA; Raebel MA
Ann Pharmacother; 1994 Feb; 28(2):252-60. PubMed ID: 8173147
[TBL] [Abstract][Full Text] [Related]
11. Fluconazole: a new antifungal agent.
Kowalsky SF; Dixon DM
Clin Pharm; 1991 Mar; 10(3):179-94. PubMed ID: 2040125
[TBL] [Abstract][Full Text] [Related]
12. [Therapy of candidiasis and cryptococcosis in AIDS].
Just-Nübling G
Mycoses; 1994; 37 Suppl 2():56-63. PubMed ID: 7609745
[TBL] [Abstract][Full Text] [Related]
13. Fluconazole: a new triazole antifungal agent.
Morrow JD
Am J Med Sci; 1991 Aug; 302(2):129-32. PubMed ID: 1897559
[TBL] [Abstract][Full Text] [Related]
14. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections.
Haria M; Bryson HM; Goa KL
Drugs; 1996 Apr; 51(4):585-620. PubMed ID: 8706596
[TBL] [Abstract][Full Text] [Related]
15. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses.
Grant SM; Clissold SP
Drugs; 1989 Mar; 37(3):310-44. PubMed ID: 2540949
[TBL] [Abstract][Full Text] [Related]
16. Antifungal prophylaxis during neutropenia or allogeneic bone marrow transplantation: what is the state of the art? Ad HOC Working Group.
Denning DW; Donnelly JP; Hellreigel KP; Ito J; Martino P; van't Wout JW
Chemotherapy; 1992; 38 Suppl 1():43-9. PubMed ID: 1611930
[TBL] [Abstract][Full Text] [Related]
17. Opportunistic fungal infections in patients with acquired immune deficiency syndrome.
Viviani MA
Chemotherapy; 1992; 38 Suppl 1():35-42. PubMed ID: 1319314
[TBL] [Abstract][Full Text] [Related]
18. Fluconazole for antifungal prophylaxis in chemotherapy-induced neutropenia.
Preston SL; Briceland LL
Am J Health Syst Pharm; 1995 Jan; 52(2):164-73; quiz 205-6. PubMed ID: 12879543
[TBL] [Abstract][Full Text] [Related]
19. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.
van der Horst CM; Saag MS; Cloud GA; Hamill RJ; Graybill JR; Sobel JD; Johnson PC; Tuazon CU; Kerkering T; Moskovitz BL; Powderly WG; Dismukes WE
N Engl J Med; 1997 Jul; 337(1):15-21. PubMed ID: 9203426
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of fluconazole 600 mg/day versus itraconazole 600 mg/day as consolidation therapy of cryptococcal meningitis in AIDS patients.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Choksawadphinyo K
J Med Assoc Thai; 2003 Apr; 86(4):293-8. PubMed ID: 12757072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
